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Abstract 
Chromosomal translocations involving the 
immunoglobulin heavy chain (IGH) locus at 14q32 
are common in mature B-cell neoplasms, but 
infrequent in B-cell acute lymphoblastic leukemia. 
Among them, the t(14;19)(q32;p13) is a rare but  
recurrent anomaly described only in a limited 
number of patients. 
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Clinics and pathology 
Disease 
B-lineage acute lymphoblastic leukaemia (ALL) 
mainly. 
Phenotype/cell stem origin 
B-lineage immunophenotype mostly positive for 
CD10, CD19, CD20, CD22, CD34, CD38, HLA-DR 
and TdT; may show aberrant expression of myeloid 
markers, CD13 and/or CD33 (Jaso et al., 2013). 
Epidemiology 
Rare anomaly, with only 16 cases reported to date; 
found most often in adolescents and young adults 
(Table 1).  
Among the reported cases there were 9 males and 7 
females aged 11 to 74 years (median age 38 years).  
13 patients were diagnosed with B-ALL (Micci et 
al., 2007; Russell et al., 2009; Chapiro et al., 2013; 
Jaso et al., 2014) and there were sporadic cases of 
other B-cell neoplasms: 1 chronic lymphocytic 
leukemia (Finn et al., 1996), 1 splenic marginal zone 
B-cell lymphoma  (Martinez-Climent et al., 2003) 
and 1 diffuse B-cell lymphoma (Micci et al., 2007). 
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Table 1: t(14;19)(q32;p13) cases
 
  Sex/Age Diagnosis Karyotype  FISH 
1. M/63  CLL 46,XY,t(14;19)(q32;p13) IGH+ 
2. F SMBCL  
48,XX,add(1)(p36),+der(1)t(1;17)(p32;q11)t(1;5)(q31;p12),+3,del(10)(p14),t(11;
12)(q23;q12),t(14;18)(q32;q21)  
47,XX,+der(1)t(1;17)t(1;5)(q31;p11),del(10),t(11;12),t(14;18),t(14;19)(q32;p13)   
  
3. 16/M  B-ALL  46,XY,t(14;19)(q32;p13) IGH+ BRD4+  
4. 36/F B-ALL  46,XX,t(14;19)(q32;p13) BRD4- 
5. 20/20/M DLBCL  50,XY,+X,+add(8)(p11),t(14;19)(q32;p13),+2mar/ 50,idem, t(1;12)(p36;q24)    
6. F/38  B-ALL  46,XX,t(9;15)(q1?;q1?),t(14;19)(q32;p13)/46,XX,add(9)(p1?),t(14;19) IGH+ EPOR+  
7. M/11 B-ALL  46,XY,t(14;19)(q32;p13) IGH+ EPOR+  
8. M/25 B-ALL  46,XY,t(14;19)(q32;p13)   IGH+ EPOR+   
9. M/38 B-ALL  46,XY,t(14;19)(q32;p13)  IGH+ EPOR+   
10
. 
F/60 B-ALL 46,XX,t(14;19)(q32;p13) No material 
11
. 
F/41  46,XX,t(14;19)(q32;p13)  IGH+ EPOR+  
12
. 
F/38 B-ALL  46,XX,t(14;19)(q32;p13)  IGH+ EPOR+  
13
. 
F/48 B-ALL  
39-47,XX,add(5)(q35),del(6)(q23),+add(8)(p23),+11,t(14;19)(q32;p13),-18,-19, 
+1-4mar   
IGH+ EPOR+  
14
. 
M/74 B-ALL  44-45,XY,-4,del(6)(q21),t(14;19)(q32;p13),del(17)(p11)  IGH+ EPOR+   
15
. 
M/21 B-ALL  
46,XY,del(12)(p12) at diagnosis 
46,XY,t(14;19)(q32;p13) at relapse  
IGH+ EPOR+   
16
. 
M/28 B-ALL  46,XY,t(14;19)(q32;p13) IGH+ EPOR+ 
   
Abreviations: M., male;  F., female; CLL., chronic lymphocytic leukemia; SMBCL., splenic marginal zone  B-
cell lymphoma; B-ALL., B-cell acute lympholastic  leukemia; DLBCL., diffuse large B-cell lymphoma. ). 
1. Finn et al., 1996; 2. Martinez-Climent et al., 2003; 3-5. Micci et  al., 2007; 6-7. Russell et al., 2009; 8-10. 
Chapiro et al., 2013; 11-16. Jaso  et al., 2014. 
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Clinics 
Patients presented with severe anemia, 
thrombocytopenia and circulating blasts in B-ALL 
patients; markedly elevated serum lactate 
dehydrogenase and serum beta-2-microglobulin 
levels may be present. Diagnostic bone marrow 
samples were hypercellular with high blast 
percentages with a median blast count of 90% (data 
from Jaso et al., 2013). 
Prognosis 
Patients with IGH/EPOR fusion descried by Jaso et 
al., 2013 received aggressive multiagent 
chemotherapy. Among them, 4 of 6 patients 
achieved an initial complete response, however all 
developed multiple relapses (median time to relapse 
was 6 months) and 5 of them died (median survival 
12 months). The 38-year-old patient described by 
Russell et al, 2007 suffered several relapses after 
diagnosis followed by bone marrow transplant 
(BMT) 4 months later; she remains alive at 13 
months after diagnosis. The second, 11-year-old boy 
achieved a complete remission, received a BMT 5 
months after diagnosis and was alive at 48 months. 
The outcome of patients described by Chapiro et al., 
2013 is known only for the 38 years old male who 
died 21 months after diagnosis. These data suggest 
that t(14;19)(q32;p13) IGH/EPOR is associated with 
an aggressive clinical course and confers a poor 
prognosis. The 2 remaining ALL patients described 
by Micci et al., 2007 achieved complete remission; 
the 16-years old with BRD4 split (see below) 
remains in remission 27 months and the 36-years old 
female relapsed after 1 year and died from 
progressive leukemia 18 months after diagnosis. 
Cytogenetics 
Cytogenetics morphological 
Cytogenetically subtle rearrangement, involving the 
telomeric end of 14q while the uncertainty of 19p or 
19q breakpoints may lead to misinterpretation of 
breakpoint positions. May resemble the appearance 
of t(14;19)(q32;q13) with IGH and BCL3 or CEBPA 
involvements in suboptimal preparations. 
Additional anomalies 
Described as the sole anomaly in 11 out of 16 cases 
(Finn et al., 1996;  Micci et al., 2007;  Russell et al 
2009;  Chapiro et al., 2013;  Jaso et al., 2014) and 
found in association with del(6q) in 2,+11 in 1, 
del(17p) in 1 (Jaso et al., 2014) and in 1 patient it 
was present in two sidelines (Russell et al., 2009).  
One patient presented  with  an  initial karyotype  of  
46,XY,del(12)(p12) and acquired the 
t(14;19)(q32;p13.1) as the sole abnormality at the 
time of relapse 39 months later (Jaso et al., 2014).  
The t(14;19)(q32;p13) was found as a part of 
complex karyotypes in both lymphoma patients 
(Martinez- Climent et al., 2003; Micci et al., 2007). 
Genes involved and 
proteins 
Note 
Involvement of EPOR (Erythropoietin Receptor 4) 
as the IGH (immunoglobulin heavy locus) partner 
gene in t(14;19)(q32;p13) has been demonstrated by 
fluorescence in situ hybridization (FISH) in patients 
with B-ALL (Russel et all., 2007; Chapiro et al., 
2013; Jaso et al., 2013). In 1 patient descried by 
Micci et al., 2007 the IGH was recombined with 
BRD4 (Bromodomain Containing 4) and in the 
second case the breakpoint on chromosome 19 was 
found in a 2.1-Mb region in 19p13.13∼19p13.2. 
 
IGH (Immunoglobulin Heavy) 
Location 
14q32.33 
 
EPOR (erythropoietin receptor) 
Location 
19p13.2 
Protein 
Inherited mutations in the erythropoietin receptor 
causing premature termination of the receptor 
cytoplasmic carboxy-terminal region have been 
described in patients with primary familial and 
congenital erythrocytosis. 
 
BRD4 (bromodomain containing 4) 
Location 
19p13.12 
Protein 
Bromodomain-containing protein 4 is a member of 
the BET (bromodomain and extra terminal domain) 
family containing 2 bromodomains that recognize 
epigenetic chromatin modifications, such as 
acetylated lysine residues. BRD4 plays a role in the 
maintenance of acute myeloid leukaemia stem cells 
and is often required for MYC expression, therefore 
it is possible that deregulated BRD4 expression may 
lead in sustained MYC expression and aberrant self-
renewal (Zuber et al., 2011). 
Result of the chromosomal 
anomaly 
Fusion protein 
Oncogenesis 
B-cell acute lymphoblastic leukemia with 
t(14;19)(q32;p13), in which IGH and EPOR are 
juxtaposed, has been reported rarely. The 
translocation was the sole abnormality in the 
majority of cases, representing an early, possibly 
initiating event. Translocations involving the 
immunoglobulin heavy chain locus results in 
t(14;19)(q32;p13) IGH/EPOR or IGH/BRD4  
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juxtaposition with IGH transcriptional enhancers to 
the partner gene leading to its deregulated 
expression. EPOR encodes a type 1 cytokine 
receptor involved in kinase signaling and is required 
for normal erythropoiesis. The principal 
consequence of t(14;19)(q32;p13) is likely over-
expression of EPOR, documented by Russel et al., 
2007. EPOR is not expressed in normal B-cell 
precursors and dysregulation of this gene may 
increase cell survival   through activation of the JAK-
STAT5. Ectopic expression of EPOR has been 
identified in B-ALL with t(12;21)(p13;q22) and 
ETV6 / RUNX1 fusion, indicating that high-level 
EPOR expression contributes to B-cell precursor 
transformation by constitutive STAT5 
phosphorylation (Dyer et al, 2010; Jasso et al., 
2014).  
 
BRD4 split by the t(14;19)(q32;p13) was found only 
in one of the two examined cases, therefore it is 
unclear if deregulation of BRD4 or the neighboring 
NOTCH3 and/or EPHX3 (ABHD9) genes, located 
distal to BRD4 in 19p13 is implicated in 
pathogenesis (Micci et al., 2007). 
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